<DOC>
	<DOCNO>NCT00145002</DOCNO>
	<brief_summary>To test superiority VCAP-AMP-VECP regimen biweekly-CHOP aggressive ATLL term survival benefit .</brief_summary>
	<brief_title>A Study Aggressive Adult T-cell Leukemia-lymphoma ( ATLL )</brief_title>
	<detailed_description>Nothing describe .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Diagnosis ATL make base seropositivity HTLVI either enzymelinked immunosorbent assay particle agglutination assay , histologically and/or cytologicallyproven peripheral Tcell malignancy 2 . Aggressive ATL , i.e. , acute , lymphoma unfavorable chronictype ATL 3 . Aged 1569 year 4 . No prior chemotherapy radiotherapy 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 03 4 result hypercalcemia 6 . Preserved organ ( bone marrow , liver , kidney , heart lung ) function 7 . All patient require provide write informed consent 1 . Diabetes mellitus necessitate treatment insulin 2 . Active systemic infection 3 . Cardiac disorder expect become bad result DOXcontaining regimen 4 . Acute hepatitis , chronic hepatitis liver cirrhosis 5 . Positive HBs Ag antiHCV Ab 6 . Active concurrent malignancy 7 . Other serious medical psychiatric condition 8 . Pregnancy breast feed 9 . Central nervous system involvement ATL cell</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ATLL</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>phase III study</keyword>
	<keyword>VCAP-AMP-VECP</keyword>
	<keyword>biweekly-CHOP</keyword>
</DOC>